Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease

2021 ◽  
Author(s):  
Sanskriti Sasikumar ◽  
Roberto Matta ◽  
Renato P. Munhoz ◽  
Mateusz Zurowski ◽  
Yu‐Yan Poon ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Dysregulation Syndrome ◽  
Advanced Therapies

scholarly journals P.042 Dopamine Dysregulation Syndrome in Parkinson’s Disease and its Management with Advanced Therapies

2021 ◽  
Vol 48 (s3) ◽  
pp. S32-S32
Author(s):  
S Sasikumar ◽  
R Matta ◽  
A Fasano
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Retrospective Chart Review ◽  
Motor Complication ◽  
Dopamine Dysregulation Syndrome ◽  
Advanced Therapies ◽  
Univariate Analyses ◽  
Stn Dbs ◽  
Deep Brain

Background: Dopamine Dysregulation Syndrome (DDS) is an adverse non-motor complication of dopamine replacement therapy in Parkinson’s Disease. The current literature on DDS is limited, and it remains underdiagnosed and challenging to manage. Methods: We performed a retrospective chart review and classified patients according to risk factors that have been identified in the literature, UPDRS scores, intervention and outcome. Univariate analyses were performed to quantify these characteristics. Results: Prior psychiatric illness was identified in 70% of patients, impulse control disorder in 89% and substance abuse in 3.7%. Interventions included reduction of dopamine therapy (88.9%), deep brain stimulation (DBS) of the subthalamic nucleus (STN, 48.1%) or globus pallidus interna (GPi, 7.4%), and levodopa-carbidopa intestinal gel (LCIG) infusion (11.1%). Baseline UPDRS IV before treatment and MDS III after treatment were not significant between intervention groups (p=0.09 and p=0.13 respectively). Overall 88.9% patients improved at follow up, with medication only (75%), STN DBS (100%), GPi DBS (100%) and LCIG (33%). Relapse rate was 18.2%, in the STN group only. Conclusions: Our results suggest that GPi DBS, in concurrence with dopaminergic medication reduction, is the most effective intervention. STN DBS might be also beneficial although the associated medications reduction causes DDS relapse in a subgroup of patients.

scholarly journals Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Phase I Clinical Trials ◽  
Preclinical Models ◽  
Preclinical Development ◽  
Dopaminergic Medication ◽  
Gene Therapies ◽  
Advanced Therapies ◽  
New Phase

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

Dopamine dysregulation syndrome with psychosis in 24-hour intestinal levodopa infusion for Parkinson's disease

2016 ◽  
Vol 28 ◽  
pp. 152-154 ◽  
Author(s):  
Lucia Ricciardi ◽  
Kristy J. Espay ◽  
Robert Krikorian ◽  
Alfonso Fasano ◽  
Alberto J. Espay
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Dysregulation Syndrome

scholarly journals Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment

2020 ◽  
Vol 26 (6) ◽  
pp. 333-342 ◽  
Author(s):  
Shoned Jones ◽  
Kelli M. Torsney ◽  
Lily Scourfield ◽  
Katie Berryman ◽  
Emily J. Henderson
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neuropsychiatric Symptoms ◽  
Treatment Strategies ◽  
Current Treatment ◽  
Motor Disorder ◽  
Dopamine Dysregulation Syndrome ◽  
Disease Aetiology ◽  
Neuropsychiatric Manifestations ◽  
Assessment Scales

SUMMARYHistorically, Parkinson's disease was viewed as a motor disorder and it is only in recent years that the spectrum of non-motor disorders associated with the condition has been fully recognised. There is a broad scope of neuropsychiatric manifestations, including depression, anxiety, apathy, psychosis and cognitive impairment. Patients are more predisposed to delirium, and Parkinson's disease treatments give rise to specific syndromes, including impulse control disorders, dopamine agonist withdrawal syndrome and dopamine dysregulation syndrome. This article gives a broad overview of the spectrum of these conditions, describes the association with severity of Parkinson's disease and the degree to which dopaminergic degeneration and/or treatment influence symptoms. We highlight useful assessment scales that inform diagnosis and current treatment strategies to ameliorate these troublesome symptoms, which frequently negatively affect quality of life.

The thrill of reckless driving in patients with Parkinson's disease: An additional behavioural phenomenon in dopamine dysregulation syndrome?

2008 ◽  
Vol 14 (3) ◽  
pp. 257-258 ◽  
Author(s):  
Maurizio Avanzi ◽  
Mario Baratti ◽  
Silvia Cabrini ◽  
Elena Uber ◽  
Gianni Brighetti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Dysregulation Syndrome ◽  
Reckless Driving

scholarly journals Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID ‐19 Experience

2020 ◽  
Vol 7 (4) ◽  
pp. 361-372 ◽  
Author(s):  
Alfonso Fasano ◽  
Angelo Antonini ◽  
Regina Katzenschlager ◽  
Paul Krack ◽  
Per Odin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Humanitarian Crisis ◽  
Advanced Therapies

Dopamine dysregulation syndrome and deep brain stimulation in patients with Parkinson's disease

2018 ◽  
Vol 46 ◽  
pp. e85
Author(s):  
S. Omarova ◽  
N. Fedorova ◽  
A. Tomskiy ◽  
A. Gamaleya ◽  
E. Bril
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Dopamine Dysregulation Syndrome ◽  
Deep Brain
Sign in / Sign up

Export Citation Format

Share Document